25 May 2013
Keywords: PhRMA, Benefit-risk assessment, BRAT framework, UMBRA, CIRS
Article | 31 January 2012
The Pharmaceutical Research and Manufacturers of America (PhRMA) says it has transferred its Benefit-Risk Action Team (BRAT) framework to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 January 2012
24 May 2013
© 2013 thepharmaletter.com